Company profile
Deep Science Ventures Limited
Home
Deep Science Ventures Limited is a UK company with status active founded in 2016 based in East of England.
Corporate ownership
Updated 06 Jun 2026 16:52
Latest accounts
Financial period: 1 Jan 2024 to 31 Dec 2024
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQzNzAxNjM1MWFkaXF6a2N4 | Paper/PDF filed
Published 28 Sep 2024 06:12
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzQzMjc2OTE1NmFkaXF6a2N4
Published 20 Aug 2024 15:11
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Bind: A new venture to exploit disordered proteins as drug targets
1 Mar 2024 to 31 Jan 2025
Overview: Many incurable diseases (cancer, neurodegeneration) involve intrinsically disordered proteins. Considered 'undruggabble' by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites to which drug-molecules can attach themselves. Our mission is to make disordered prote...
Bind: A new venture to exploit disordered proteins as drug targets
1 Mar 2024 to 31 Jan 2025
Overview: Many incurable diseases (cancer, neurodegeneration) involve intrinsically disordered proteins. Considered 'undruggabble' by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites to which drug-molecules can attach themselves. Our mission is to make disordered prote...
ICURe - venture creation
1 Apr 2022 to 31 Mar 2025
ICURe - venture creation
1 Apr 2022 to 31 Mar 2023
ICURe - venture creation
1 Apr 2022 to 31 Mar 2023
Development of clinically translatable therapies for the treatment and prevention of bacterial vaginosis
1 Feb 2020 to 31 Oct 2021
This research aims to develop new therapies for the treatment of recurrent bacterial vaginosis (BV). BV is the most common vaginal infection experienced by women of childbearing age, with up to 30% of woman of this group affected by the condition. BV is caused by the overgrowth of unwanted bacteria within the vagina. The main problematic bacterium which c...